Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

12 Zoekresultaten.

Eligibility NCT00796757 Renal Cell Cancer - Eligibility

- 09-12-13 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00796757

Eligibility NCT00655252 Metastatic Renal Cell Cancer - Eligibility

- 09-12-13 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00655252

Eligibility DRKS00004096 NCT00688753 Carcinoma - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00688753

Eligibility Criteria NCT00044564 - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 7 Data-elementen, 1 Taal

Itemgroepen: Inclusion criteria, Exclusion criteria

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 27-11-24 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal

Itemgroep: IG.elig

Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 Itemgroep 5 Data-elementen

pht004835.v1.p1

1 Itemgroep 5 Data-elementen

pht004836.v1.p1

1 Itemgroep 16 Data-elementen

pht004837.v1.p1

1 Itemgroep 5 Data-elementen

dbGaP phs000397 NIA Long Life Family Study (LLFS) - Eligibility

- 12-10-22 - 6 Formulieren, 1 Itemgroep, 3 Data-elementen, 1 Taal

Itemgroep: IG.elig

Principal Investigator: Michael A. Province, PhD, Washington University School of Medicine, St. Louis, MO, USA MeSH: Longevity,Aging,Cardiovascular Diseases,Neoplasms,Stroke,Inflammation,Immune System,Diabetes Mellitus,Hypertension,Dyslipidemias,Lipids,Osteoporosis,Pulmonary Function Tests,Kidney Function Tests,Alzheimer Disease,Depression,Personality,Executive Function,Reproductive History https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000397 The Long Life Family Study (LLFS) is an international collaborative study of the genetics and familial components of exceptional survival, longevity, and healthy aging. Families were recruited through elderly probands (generally in their 90s) who self-reported on the survival history of their parents and siblings, and on the basis of this information, families which showed clustering of exceptional survival were recruited. [Specifically, a Family Longevity Selection Score (FLOSS) ≥7 was required. The FLOSS measures the average excess Observed lifespan over that Expected based upon lifetables, while adding a bonus term for still-living individuals. Thus FLOSS is a useful tool for scoring and selecting families for inclusion in a research study of exceptional survival (Sebastiani et al., 2009, PMID: 19910380)]. Probands resided in the catchment areas of four Field Centers (Boston University, Columbia University, University of Pittsburgh, and University of Southern Denmark). Recruited family members were phenotyped through extensive in-home visits by teams of technicians who traveled all over the USA and Denmark. Blood assays were centrally processed at a Laboratory Core (University of Minnesota) and protocols were standardized, monitored and coordinated through a Data Management Coordinating Center (Washington University). We examined and extensively phenotyped in all major domains of healthy aging, 4,953 individuals in 539 families through comprehensive in-home visits. Of these, 4,815 gave dbGaP sharing permission and had sufficient quantity/quality of DNA for GWAS genotyping. This large collection of families, selected on the basis of clustering for exceptional survival, is a unique resource for the study of human longevity and healthy aging. We estimate that less than 1% of the Framingham Heart Study (FHS) families (a roughly random population family sample) would meet the minimal entrance criteria for exceptional survival required in the LLFS (Sebastiani et al., 2009, PMID: 19910380). Thus, the least exceptional LLFS families show more clustering for exceptional longevity than 99% of the FHS families. Although the LLFS pedigrees were selected on the basis of longevity per se in the upper generation (and the generation above that), the children's generation have significantly lower rates of many major diseases and have better healthy aging profiles for many disease phenotypes (Newman et al., 2011, PMID: 21258136). The participants had their first in-person visit between 2006 and 2009. After that visit, they were contacted annually by telephone to update vital status, medical history, and general health. Between 2014 and 2017, willing participants completed a second in-person visit. The second visit followed the same protocols and centralized training as the first visit. During the second visit, a portable carotid ultrasound exam was added. Again, participants were continuously contacted annually for telephone follow-up during the period of the second in-person visit and after that. Annual telephone follow-ups currently ongoing, and plans for a third in-person visit are in progress.

pht002407.v3.p3

1 Itemgroep 4 Data-elementen

pht002408.v3.p3

1 Itemgroep 6 Data-elementen

pht002410.v3.p3

1 Itemgroep 106 Data-elementen

pht003356.v3.p3

1 Itemgroep 4 Data-elementen

pht002409.v3.p3

1 Itemgroep 3 Data-elementen

Eligibility DRKS00009656 NCT00069745 Prostate Cancer - Eligibility

- 20-09-21 - 1 Formulier, 3 Itemgroepen, 34 Data-elementen, 2 Talen

Itemgroepen: Inclusion criteria, Exclusion criteria, Medical Concepts

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Inclusion Criteria: - Stage D2 metastatic prostate cancer - Progression after one prior chemotherapy - ECOG Performance status equal / less than 2 - Life expectancy > 3 months - Surgical or medical castration - Adequate bone marrow, hepatic and renal functions - Informed consent Exclusion Criteria: - More than one prior chemotherapy - Prior platinum containing compounds - Prior malignancy - Prior significant RT/radionuclide therapy - Major GI surgery or GI disease affecting absorption - Disease with contraindication to steroids - Brain metastases

Eligibility NCT00053768 NHL - Eligibility

- 17-09-21 - 1 Formulier, 3 Itemgroepen, 33 Data-elementen, 2 Talen

Itemgroepen: Disease characteristics, Patient characteristics and prior concurrent therapy, Medical Concepts

Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma DISEASE CHARACTERISTICS: - Histologically confirmed aggressive non-Hodgkin's lymphoma - Previously untreated disease - Favorable prognosis - International Prognostic Index score of 0-1 - No more than 25% marrow involvement PATIENT CHARACTERISTICS: Age - 18 to 60 Performance status - ECOG 0-3 OR - Karnofsky 40-100% Life expectancy - Not specified Hematopoietic - Platelet count at least 100,000/mm^3 - WBC at least 2,500/mm^3 Hepatic - No active hepatitis infection Renal - Not specified Other - HIV negative - Not pregnant or nursing - No relevant accompanying disease - No other concurrent malignancy - No contraindications to any study medications - No prior noncompliance by patient PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy Surgery - Not specified Other - No other concurrent participation in another treatment study

dbGaP phs001287 CPTAC 3 Study - Eligibility

- 13-03-23 - 3 Formulieren, 1 Itemgroep, 9 Data-elementen, 1 Taal

Itemgroep: IG.elig

Principal Investigator: MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287 Recently, significant progress has been made in characterizing and sequencing the genomic alterations in statistically robust numbers of samples from several types of cancer. For example, The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and other similar efforts are identifying genomic alterations associated with specific cancers (e.g., copy number aberrations, rearrangements, point mutations, epigenomic changes, etc.) The availability of these multi-dimensional data to the scientific community sets the stage for the development of new molecularly targeted cancer interventions. Understanding the comprehensive functional changes in cancer proteomes arising from genomic alterations and other factors is the next logical step in the development of high-value candidate protein biomarkers. Hence, proteomics can greatly advance the understanding of molecular mechanisms of disease pathology via the analysis of changes in protein expression, their modifications and variations, as well as protein=protein interaction, signaling pathways and networks responsible for cellular functions such as apoptosis and oncogenesis. Realizing this great potential, the NCI launched the third phase of the CPTC initiative in September 2016. As the Clinical Proteomic Tumor Analysis Consortium, CPTAC continues to define cancer proteomes on genomically-characterized biospecimens. The purpose of this integrative approach was to provide the broad scientific community with knowledge that links genotype to proteotype and ultimately phenotype. In this third phase of CPTAC, the program aims to expand on CPTAC II and genomically and proteomically characterize over 2000 samples from 10 cancer types (Lung Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Glioblastoma Multiforme, Acute Myeloid Leukemia, Clear cell renal Carcinoma, Head and Neck Squamous Cell Carcinoma, Cutaneous Melanoma, Sarcoma, Lung Squamous Cell Carcinoma, Uterine Corpus Endometrial Carcinoma) .Germline DNA is obtained from blood and Normal control samples for proteomics varied by organ site. All cancer samples were derived from primary and untreated tumor.

Neoplasms

pht006104.v9.p5

1 Itemgroep 3 Data-elementen

pht006105.v9.p5

1 Itemgroep 3 Data-elementen

dbGaP phs000495 The Gene Partnership (TGP) - eMERGE Data - Eligibility

- 13-12-22 - 5 Formulieren, 1 Itemgroep, 7 Data-elementen, 1 Taal

Itemgroep: IG.elig

Principal Investigator: Isaac S. Kohane, MD, PhD, Boston Children's Hospital, Boston, MA, USA MeSH: Autistic Disorder,Heart Defects, Congenital,Asthma,Attention Deficit Disorders,Diabetes Mellitus, Type 1,Diabetes Mellitus, Type 2,Epilepsy,Gastrointestinal Diseases,Hypersensitivity,Autoimmune Diseases,Hematologic Diseases,Neoplasms,Arrhythmias, Cardiac,Chromosome Aberrations,Congenital Abnormalities,Dermatology,Developmental Disabilities,Endocrine System,Otolaryngology,Syndrome,Urogenital System,Hearing Loss,Immune System Diseases,Musculoskeletal Abnormalities,Nervous System Diseases,Neuromuscular Diseases,Metabolic Diseases,Nutrition Disorders,Vision Disorders,Mouth Diseases,Mental Disorders,Kidney Diseases,Respiration Disorders,Thyroid Diseases,Vascular Diseases https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000495 The Gene Partnership (TGP) is a prospective longitudinal registry at Boston Children's Hospital (BCH) to study the genetic and environmental contributions to childhood health and disease, collect genetic information on a large number of children who have been phenotyped, and implement the Informed Cohort and the Informed Cohort Oversight Board (ICOB). The term "*The Gene Partnership*" reflects a partnership between researchers and participants. Children seen at BCH are offered enrollment, as are their parents and siblings. DNA is collected on all enrollees. BCH has a comprehensive EMR system, and virtually all inpatient and outpatient data are captured electronically. Clinical data in the BCH EMR is loaded in the i2b2 data warehouse which is available to investigators. Cases, phenotypes, and covariates are ascertained using the i2b2 database. Participants at BCH in TGP have consented to receive any research result and/or incidental finding that arises from studies using TGP that is approved by the Informed Cohort Oversight Board (ICOB) and is in accordance with the participants' preferences; results are returned through the Personally Controlled Health Record (PCHR). BCH and Cincinnati Children's Hospital Medical Center (CCHMC) have partnered as the *P*ediatric *A*lliance for *G*enomic and *E*lectronic Medical Record (EMR) *R*esearch (*PAGER*) site for the eMERGE Phase II network for pediatric institutions, and the cohort for eMERGE at BCH is TGP.

pht002864.v1.p1

1 Itemgroep 4 Data-elementen

pht002865.v1.p1

1 Itemgroep 5 Data-elementen

pht002866.v1.p1

1 Itemgroep 42 Data-elementen

pht002867.v1.p1

1 Itemgroep 4 Data-elementen

dbGaP phs001052 Multi-Dimensional ClinOmics for Precision Therapy - Eligibility

- 09-07-23 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal

Itemgroep: IG.elig

Principal Investigator: MeSH: Neoplasms,Sarcoma,Sarcoma, Ewing,Rhabdomyosarcoma,Wilms Tumor,Desmoplastic Small Round Cell Tumor,Carcinoma, Transitional Cell,Rhabdoid Tumor,Sarcoma, Synovial,Neuroblastoma,Neuroendocrine tumors https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001052 The Center for Cancer Research (CCR), of the intramural NCI undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers who were enrolled on other therapeutic trials to determine the feasibility of a genome guided precision therapy protocol in these patients.

pht005466.v2.p1

1 Itemgroep 2 Data-elementen

pht005467.v2.p1

1 Itemgroep 3 Data-elementen

pht005468.v2.p1

1 Itemgroep 3 Data-elementen

pht005469.v2.p1

1 Itemgroep 6 Data-elementen

ACNS1123 Eligibility - FP.0000

- 02-06-15 - 1 Formulier, 11 Itemgroepen, 42 Data-elementen, 1 Taal

Itemgroepen: STRATIFICATION, TUMOR LOCATION Elig - Block 1, TUMOR LOCATION Elig - Block 2, INCLUSION CRITERIA - NGGCT STRATUM 1, INCLUSION CRITERIA - Germinoma STRATUM 2, ORGAN FUNCTION REQUIREMENT - Bone Marrow Function, ORGAN FUNCTION REQUIREMENT - Renal Function, ORGAN FUNCTION REQUIREMENT - Liver Function, CENTRAL NERVOUS SYSTEM FUNCTION, EXCLUSION CRITERIA, REGULATORY

ACNS1123 Eligibility Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.